Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Galardi F, De Luca F, Biagioni C, Migliaccio I, Curigliano G, Minisini AM, Bonechi M, Moretti E, Risi E, McCartney A, Benelli M, Romagnoli D, Cappadona S, Gabellini S, Guarducci C, Conti V, Biganzoli L, Di Leo A, Malorni L. Galardi F, et al. Among authors: biagioni c. Breast Cancer Res. 2021 Mar 24;23(1):38. doi: 10.1186/s13058-021-01415-w. Breast Cancer Res. 2021. PMID: 33761970 Free PMC article. Clinical Trial.
Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?
Biganzoli L, Boni L, Becheri D, Zafarana E, Biagioni C, Cappadona S, Bianchini E, Oakman C, Magnolfi SU, Di Leo A, Mottino G. Biganzoli L, et al. Among authors: biagioni c. Ann Oncol. 2013 Feb;24(2):494-500. doi: 10.1093/annonc/mds331. Epub 2012 Oct 7. Ann Oncol. 2013. PMID: 23045516 Free article.
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Jeselsohn R, Barry WT, Migliaccio I, Biagioni C, Zhao J, De Tribolet-Hardy J, Guarducci C, Bonechi M, Laing N, Winer EP, Brown M, Leo AD, Malorni L. Jeselsohn R, et al. Among authors: biagioni c. Clin Cancer Res. 2016 Dec 1;22(23):5755-5764. doi: 10.1158/1078-0432.CCR-16-0148. Epub 2016 May 16. Clin Cancer Res. 2016. PMID: 27185372 Free PMC article. Clinical Trial.
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Malorni L, Piazza S, Ciani Y, Guarducci C, Bonechi M, Biagioni C, Hart CD, Verardo R, Di Leo A, Migliaccio I. Malorni L, et al. Among authors: biagioni c. Oncotarget. 2016 Sep 13;7(42):68012-68022. doi: 10.18632/oncotarget.12010. Oncotarget. 2016. PMID: 27634906 Free PMC article.
Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools.
Biganzoli L, Mislang AR, Di Donato S, Becheri D, Biagioni C, Vitale S, Sanna G, Zafarana E, Gabellini S, Del Monte F, Mori E, Pozzessere D, Brunello A, Luciani A, Laera L, Boni L, Di Leo A, Mottino G. Biganzoli L, et al. Among authors: biagioni c. J Gerontol A Biol Sci Med Sci. 2017 Jul 1;72(7):922-928. doi: 10.1093/gerona/glw234. J Gerontol A Biol Sci Med Sci. 2017. PMID: 28158486
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L. Risi E, et al. Among authors: biagioni c. Breast Cancer Res Treat. 2018 Jul;170(2):329-341. doi: 10.1007/s10549-018-4766-2. Epub 2018 Mar 22. Breast Cancer Res Treat. 2018. PMID: 29564743
67 results